Periscope Capital’s Gilead Sciences GILD Stock Holding History

Periscope Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,590	Closed	-$254K	–	175
2018 Q2	$254K	Buy	+3,590	New	+$254K	0.05%	125

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Periscope Capital's GILD Position: Q3 2018 in Review

Periscope Capital sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 3,590 shares — an estimated $254K sold.

Periscope Capital first reported a position in GILD in Q2 2018 and held it in 1 quarter. The position peaked at $254K in Q2 2018. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Periscope Capital reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
Periscope Capital sold 3,590 Gilead Sciences shares in Q3 2018, an estimated $254K.
Periscope Capital first reported a position in Gilead Sciences in Q2 2018 and held it in 1 quarter.
Periscope Capital's Gilead Sciences position peaked at $254K in Q2 2018.
1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Periscope Capital's 13F filing for Q3 2018, filed 8 Nov 2018.